Supplements and Featured Publications
Metastatic Castration-Sensitive Prostate Cancer Treatment Updates
Updates in the Management of Non-Muscle Invasive Bladder Cancer
Treatment Options in Metastatic Castration-Resistant Prostate Cancer
In this K-Cast video series, Neal Shore, MD, describes current standards in the treatment of metastatic castration-resistant prostate cancer (mCRPC) and provides an overview of data from the PROfound trial. Also discussed are genetic testing in mCRPC, the impact of coronavirus disease 2019 on patient care, the role of PARP inhibitors in patients with mCRPC, and considerations for the management of mCRPC.
Clinical Spotlight: Benign Prostatic Hyperplasia
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
2
Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring
3
Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC
4
FDA approves adjuvant belzutifan with pembrolizumab for ccRCC
5